Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07145151Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of UBT251 in metabolic dysfunction-associated steatohepatitis (MASH). Started Sep 2025; status: recruiting.
02
Drugs
UBT251
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07145151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145151.